Brand Intelligence Graph
Company Overview
About EpiBiologics
EpiBiologics develops EpiTAC — a targeted protein degradation platform designed to eliminate membrane and secreted proteins that existing degrader technologies cannot reach. The company raised $107 million in Series B financing in January 2026, co-led by Johnson & Johnson Ventures and Google Ventures, a rare investor pairing that brings both pharma development expertise and computational biology capabilities. The lead program, EPI-326 (an EGFR degrader for non-small cell lung cancer), is entering Phase 1 clinical trials in the first half of 2026.
Business Model & Competitive Advantage
Targeted protein degradation (TPD) — using molecular glues and PROTACs to hijack the cell's own protein disposal machinery — has become one of oncology's most active drug discovery fields. However, the majority of current degraders can only reach intracellular targets: the proteins inside the cell. EpiBiologics' EpiTAC platform extends degradation to membrane-bound receptors (including growth factor receptors and immune checkpoints) and secreted proteins in the extracellular space — dramatically broadening the target class that degradation approaches can address.
Competitive Landscape 2025–2026
J&J Ventures' co-lead is particularly significant given Janssen's deep oncology portfolio and history of acquiring precision oncology assets: EpiBiologics' platform access to targets like EGFR — which has driven multiple Janssen-adjacent drug classes — signals potential strategic interest in both the technology and the clinical assets.
Key Differentiators
Emerging Innovator
EpiBiologics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare EpiBiologics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from EpiBiologics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim EpiBiologics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention EpiBiologics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →